Filgrastim for the treatment of hematopoietic acute radiation syndrome.

• Autores: A.M. Farese, T.J. MacVittie
• Localización: Medicamentos de actualidad = Drugs of today, ISSN 1699-3993, Vol. 51, Nº. 9, 2015, págs. 537-548
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The U.S. Food and Drug Administration (FDA) recently approved Neupogen(R) (filgrastim) for the treatment of patients with radiation-induced myelosuppression following a radiological/nuclear incident. It is the first medical countermeasure currently approved by the FDA for this indication under the criteria of the FDA "animal rule". This article summarizes the consequences of high-dose radiation exposure, a description of the hematopoietic acute radiation syndrome (H-ARS), the use of hematopoietic growth factors in radiation accident victims and current available treatments for H-ARS with an emphasis on the use of Neupogen in this scenario.